Objective:

To determine the effectiveness of Tapentadol in cancer patients with neuropathic pain.

Material and methods:

A descriptive, longitudinal, observational and prospective study was carried out including patients with cancer diagnosis and neuropathic pain treated at the pain clinic between January 1, 2014 and December 31, 2019.

Results:

63 patients with a mean age of 59.07 ± 11.06 years were included, of which 76.2% (n = 48) were female. In the EVERA (verbal analog scale) and DN4 (neuropathic pain in 4 questions) scales, a significant difference was observed after treatment and when Tapentadol was initially used, a lower proportion of adverse effects was observed.

Conclusions:

Tapentadol proved to be an equally effective tool as other treatments, both as an initial or rotation drug, and when used as first line, it had better tolerability.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )